Abali Huseyin, Oyan Basak, Koc Yener, Kars Ayse, Barista Ibrahim, Uner Aysegul, Turker Alev, Demirkazik Figen, Tekin Fatma, Tekuzman Gulten, Kansu Emin
Hacettepe University, Institute of Oncology, Ankara, Turkey.
Am J Clin Oncol. 2005 Jun;28(3):264-9. doi: 10.1097/01.coc.0000145984.39639.0d.
Patients with relapsed lymphoma can be cured with high-dose chemotherapy and autologous hematopoietic stem cell transplantation (HSCT). New therapeutic approaches with better cytoreductive capacity are needed for relapsed patients to keep their chance for cure with transplantation. We report 30 patients with relapsed lymphoma, median age 43 years, treated with IIVP salvage regimen consisting of ifosfamide, mesna, idarubicin, and etoposide for 2 or 3 cycles. Seventeen patients had non-Hodgkin lymphoma (NHL) and 13 patients had Hodgkin disease (HD). Fourteen (47%) patients were at their first relapse. Overall response rate was 86.6% (n = 26) with 19 patients (63.3%) achieving complete response. Overall response rate was 92% in patients with HD and 82% in NHL. The most frequent side effects observed were grade III-IV neutropenia (87%) and thrombocytopenia (73%). IIVP regimen is a highly effective salvage therapy for patients with relapsed HD or NHL who are candidates for autologous HSCT. Close follow up is necessary because of the high incidence of grade III-IV hematologic toxicity.
复发性淋巴瘤患者可通过大剂量化疗和自体造血干细胞移植（HSCT）治愈。对于复发性患者，需要有更好细胞减灭能力的新治疗方法来维持其移植治愈的机会。我们报告了30例复发性淋巴瘤患者，中位年龄43岁，接受了由异环磷酰胺、美司钠、伊达比星和依托泊苷组成的IIVP挽救方案治疗2或3个周期。17例患者患有非霍奇金淋巴瘤（NHL），13例患者患有霍奇金病（HD）。14例（47%）患者为首次复发。总缓解率为86.6%（n = 26），19例患者（63.3%）达到完全缓解。HD患者的总缓解率为92%，NHL患者为82%。观察到的最常见副作用为III-IV级中性粒细胞减少（87%）和血小板减少（73%）。IIVP方案对于适合自体HSCT的复发性HD或NHL患者是一种高效的挽救治疗方法。由于III-IV级血液学毒性发生率高，密切随访是必要的。
